Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)
46.98 x 1 51.03 x 1
Post-market by (Cboe BZX)
49.46 -0.51 (-1.02%) 01/31/25 [NASDAQ]
46.98 x 1 51.03 x 1
Post-market 49.46 unch (unch) 16:03 ET
Quote Overview for Fri, Jan 31st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
48.27
Day High
50.49
Open 49.68
Previous Close 49.97 49.97
Volume 1,099,055 1,099,055
Avg Vol 1,188,193 1,188,193
Stochastic %K 58.60% 58.60%
Weighted Alpha -35.35 -35.35
5-Day Change -1.29 (-2.54%) -1.29 (-2.54%)
52-Week Range 44.49 - 84.05 44.49 - 84.05
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,897,160
  • Shares Outstanding, K 118,014
  • Annual Sales, $ 7,530 K
  • Annual Income, $ -526,240 K
  • EBIT $ -525 M
  • EBITDA $ -513 M
  • 60-Month Beta 0.82
  • Price/Sales 1,664.48
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 55.04% ( +7.68%)
  • Historical Volatility 36.80%
  • IV Percentile 29%
  • IV Rank 33.43%
  • IV High 97.36% on 05/07/24
  • IV Low 33.79% on 06/03/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 686
  • Volume Avg (30-Day) 2,050
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 32,209
  • Open Int (30-Day) 54,439

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.24
  • Number of Estimates 12
  • High Estimate -0.59
  • Low Estimate -1.60
  • Prior Year -1.38
  • Growth Rate Est. (year over year) +10.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.49 +11.17%
on 01/13/25
Period Open: 47.04
52.80 -6.33%
on 01/27/25
+2.42 (+5.14%)
since 12/31/24
3-Month
44.49 +11.17%
on 01/13/25
Period Open: 51.00
59.39 -16.72%
on 11/11/24
-1.54 (-3.02%)
since 10/31/24
52-Week
44.49 +11.17%
on 01/13/25
Period Open: 78.73
84.05 -41.15%
on 02/02/24
-29.27 (-37.18%)
since 01/30/24

Most Recent Stories

More News
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

CYTK : 49.46 (-1.02%)
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

CYTK : 49.46 (-1.02%)
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

CYTK : 49.46 (-1.02%)
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CYTK : 49.46 (-1.02%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

CYTK : 49.46 (-1.02%)
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

CYTK : 49.46 (-1.02%)
Why Cytokinetics Stock Was a Nearly 5% Winner Today

California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in...

CYTK : 49.46 (-1.02%)
SNY : 54.34 (+0.35%)
Cytokinetics Announces Sanofi's Acquisition of Aficamten Development Rights for Greater China

Sanofi will acquire exclusive rights to aficamten for treating hypertrophic cardiomyopathy in Greater China from Corxel Pharmaceuticals.Quiver AI SummaryCytokinetics, Inc. announced that Sanofi will acquire...

CYTK : 49.46 (-1.02%)
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

CYTK : 49.46 (-1.02%)
Insider Sale: EVP Research & Development of $CYTK (CYTK) Sells 5,300 Shares

Fady Ibraham Malik, the EVP Research & Development of $CYTK ($CYTK), sold 5,300 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

CYTK : 49.46 (-1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 52.76
2nd Resistance Point 51.63
1st Resistance Point 50.54
Last Price 49.46
1st Support Level 48.32
2nd Support Level 47.19
3rd Support Level 46.10

See More

52-Week High 84.05
Fibonacci 61.8% 68.94
Fibonacci 50% 64.27
Fibonacci 38.2% 59.60
Last Price 49.46
52-Week Low 44.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Exclusive Barchart Webinar: Unlock the Power of High-Accuracy Option Trading